Articles
- Anti-CD19 CAR T-Cells Show Promise in B-Cell Cancer
- Lenvatinib Prolongs Progression-Free Survival in Advanced Thyroid Cancer
- Ruxolitinib More Effective Than Standard Therapy in the Treatment of Polycythemia Vera
By Wayne Kuznar
An investigational first-in-class anticancer quinolone derivative, vosaroxin, extended median overall survival (OS) when used with cytarabine (Cytosar-U) in a phase 3 clinical trial of patients with relapsed or refractory acute myeloid leukemia (AML), although the difference was not significant. Read More ›
By Wayne Kuznar
Disease progression is slower and overall survival (OS) is greater in patients with chronic myeloid leukemia (CML) who are being monitored for their response to tyrosine kinase inhibitor (TKI) therapy and show good adherence. However, few clinicians monitor response and adherence to oral TKI treatment in patients with CML. Read More ›
We interviewed Hi (Jenny) An, PharmD, Pharmacy Supervisor at the Virginia K. Crosson Cancer Center, St. Joseph’s Healthcare System, in Fullerton, CA, about her unique experiences in oncology pharmacy. Read More ›
- Dinutuximab FDA-Approved for Pediatric Patients with High-Risk Neuroblastoma
- First HDAC Inhibitor, Panobinostat, Approved for Patients with Multiple Myeloma
- Palbociclib Approved for Metastatic Breast Cancer in Postmenopausal Women
- FDA Expedites Approval of Lenvatinib for Refractory Differentiated Thyroid Cancer
- Nivolumab First Immunotherapy to Get FDA Approval for Metastatic Lung Cancer
- Lenalidomide Combined with Dexamethasone Receives Expanded Indication for Patients with Newly Diagnosed Myeloma
In this month’s issue ofThe Oncology Pharmacist (TOP), we present our coverage of the news from the 11th annual Hematology/Oncology Pharmacy Association (HOPA) conference. TOP was there, and we highlight presentations about the role of pharmacists in hospice and palliative care, the disposal of oral cancer drugs, and opportunities in survivorship care. Read More ›
We see a number of changes you might make to improve your financial security, but one item is usually beyond your control: your 401(k) plan. Unless you are self-employed, there is practically nothing you can do if your 401(k) has limited investment options, low contribution limits, or tax consequences. Read More ›
In 1962, President John F. Kennedy challenged Americans to go to the moon within a decade. Apollo 11 accomplished that goal 7 years later. In 2012, inspired by that challenge, the University of Texas MD Anderson Cancer Center launched the Moon Shots Program. This ambitious plan aims to convert scientific discoveries into clinical advances quickly to improve survival rates for several of the deadliest cancers including ovarian cancer, which is our focus this month. Read More ›
To what extent should the pharmacist be included in hospice and palliative care, and how can their skills and knowledge best be utilized? Read More ›
By Chase Doyle
Data presented at the 2015 Gastrointestinal Cancers Symposium illustrated that the biosimilar epoetin alfa (HX575, Binocrit) can safely correct anemia and maintain hemoglobin levels. Read More ›